Listed by the USPTO as AGGARWAL, SAHIL CHANDER
Tech Center 1600 • Art Units: 1623
This examiner grants 67% of resolved cases
Sahil Chander Aggarwal is an examiner in Tech Center 1600 and Art Unit 1623, with 3 resolved cases. The allowance rate is 66.7%, and the median time to allowance is 942 days. The data shows an interview lift of 0.0%, suggesting that interviews have not historically changed outcomes in this limited sample. Top companies include Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc., and Prilenia Neurotherapeutics Ltd. The firms BakerHostetler, NOVICK, KIM & LEE, PLLC, and ROTHWELL, FIGG, ERNST & MANBECK, P.C. are active.
The 66.7% allowance rate is based on a small set of 3 resolved cases, which should be considered when evaluating performance. A median pendency of 942 days provides an initial baseline for prosecution timing in Art Unit 1623. The 0.0% interview lift indicates that, thus far, interviews have not resulted in a statistical increase in allowances. For Bristol-Myers Squibb Company, the 66.7% rate is the primary metric available. Practitioners should monitor this examiner as more cases are resolved to see if the 0.0% lift persists. The 942-day median pendency suggests a standard timeline for the biotech sector.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18504196 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18687372 | PROCESS FOR THE PREPARATION OF AN OPTICALLY ACTIVE ISOXAZOLINE COMPOUND | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18714407 | MATERIAL FOR PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING, AND PHOTOELECTRIC CONVERSION ELEMENT | Non-Final OA | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. |
| 18249581 | PEG-FREE AQUEOUS SUSPENSIONS FOR PARENTERAL ADMINISTRATION OF A CORTICOSTEROID | Non-Final OA | Pfizer Inc. |
| 18858418 | Oxazepin Derivative | Non-Final OA | TEIJIN PHARMA LIMITED |
| 18859285 | METHOD FOR PRODUCING TITANIUM-CONTAINING SILICON OXIDE, METHOD FOR PRODUCING EPOXIDE, AND TITANIUM-CONTAINING SILICON OXIDE | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18792949 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Non-Final OA | Ripple Therapeutics Corporation |
| 18422011 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Non-Final OA | UNIVERSAL DISPLAY CORPORATION |
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | Non-Final OA | AARDVARK THERAPEUTICS INC. |
| 18846616 | MULTICYCLIC COMPOUNDS | Non-Final OA | Antares Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy66.7% of resolved applications examined by Sahil Chander Aggarwal were allowed (3 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sahil Chander Aggarwal took 942 days on average from filing to allowance.
Sahil Chander Aggarwal examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
